Health Care Equipment

GlucoTrack

GlucoTrack released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0, actual EPS USD -4.6374

GlucoTrack released FY2025 9 Months earnings on November 13 (EST), actual revenue USD 0, actual EPS USD -54.6045

GlucoTrack released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -9.6177

GlucoTrack released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -34.809

GlucoTrack Inc. Repurchased Warrants to Strengthen Capital Structure

GlucoTrack Inc. Reports Positive First-in-Human Study Results for Continuous Blood Glucose Monitor

Glucotrack to Showcase Advanced Continuous Glucose Monitoring Technology

Glucotrack Inc. to Hold a Webinar on Its CBGM Technology

GlucoTrack released FY2025 Q1 earnings on May 14 (EST) with actual revenue of USD 0 and EPS of USD -40.3493

GlucoTrack Expects FDA Approval in Q4 2025

GlucoTrack Inc. Secures Ethical Approval for Long-term CGM Clinical Trial

GlucoTrack released FY2024 Q4 earnings on March 31, 2025 (EST) with actual revenue USD 0 and EPS USD 0

GlucoTrack released FY2024 Annual Earnings on March 31 (EST) with actual revenue of USD 0 and EPS of USD 0

GlucoTrack Prices 2.6 Million Shares at $1.15 Each to Raise Approximately $3 Million

Glucotrack, Inc. Completes First Human Clinical Study, Continuous Blood Glucose Monitoring Device Successfully Achieves Primary Endpoint

Glucotrack Obtains ISO 13485:2016 Certification, Marking a Significant Milestone in Quality Commitment for Continuous Blood Glucose Monitoring Devices

GlucoTrack released FY2024 Q3 earnings on November 14, 2024 (EST) with actual revenue of USD 0 and EPS of USD 0

GlucoTrack released FY2024 9 Months Earnings on November 14, 2024 (EST) with actual revenue of USD 0 and EPS of USD 0

GlucoTrack released FY2024 Q2 earnings on August 13 (EST) with actual revenue of USD 0 and EPS of USD 0

GlucoTrack released FY2024 Semi-Annual Earnings on August 13, 2024 (EST) with actual revenue of USD 0 and EPS of USD 0

A SPAC III Acquisition

PicoCELA

ECD Automotive Design

Northann

Davis Commodities

Paranovus ENT Tech

Titan Mining

Bristol-Myers Squibb Company

Gauzy

Can-Fite BioPharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap